CJC-1295 With DAC Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: Limited early-phase human pharmacodynamic data on GH and IGF-1 elevation.

Animal evidence: Preclinical GHRH-receptor and pharmacokinetic studies.

Introduction & Mechanism of Action

GHRH analog with drug-affinity complex studied for extended-duration growth-hormone pulse research.

GHRH(1-29) analog conjugated to a drug-affinity complex that binds serum albumin, extending its half-life dramatically versus native GHRH or no-DAC variants — supports less-frequent dosing at the cost of less-pulsatile GH release.

Receptors/targets: GHRH receptor

Areas of Research Interest

• Growth-hormone pulse research
• Body-composition studies

Benefits Reported in Research

• Growth-hormone pulse research
• Body-composition studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 1–2 mg

Reported frequency: 2× weekly, subcutaneous

Reported cycle duration: 8–12 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on CJC-1295 With DAC reports administration at 1–2 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Injection-site reaction
• Water retention
• Flushing

Contraindications

• Active malignancy (theoretical concern)
• Pregnancy

Drug interactions

• Ghrelin-receptor agonists (e.g. Ipamorelin, GHRP-2/6) — commonly combined for additive GH-pulse effect

Safety

• Sustained (rather than pulsatile) GH elevation raises theoretical long-term-exposure questions distinct from shorter-acting GHRH analogs
• Injection-site reactions

The drug-affinity complex extends half-life substantially versus no-DAC variants; evidence for either is limited.

Expected Results & Comparison

The defining difference from CJC-1295 No DAC is duration: the DAC variant's albumin-binding extends its half-life from hours to days, trading a more natural pulsatile GH release for dosing convenience — a real pharmacokinetic tradeoff, not simply a stronger/weaker distinction.

References

Continue